Evaluation of Effectiveness and Tolerability of Fondaparinux in the Management of Symptomatic Acute Coronary Syndrome: A Real-World Evidence-Based Study on an Indian Population.
ACS
EMR
Fondaparinux
Real-world evidence
Stent thrombosis
Journal
Cardiology and therapy
ISSN: 2193-8261
Titre abrégé: Cardiol Ther
Pays: England
ID NLM: 101634495
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
04
10
2021
accepted:
10
01
2022
pubmed:
10
2
2022
medline:
10
2
2022
entrez:
9
2
2022
Statut:
ppublish
Résumé
Fondaparinux is a low molecular weight heparin anticoagulant used to manage the full spectrum of acute coronary syndrome (ACS) patients and has proved its efficacy and safety in multiple clinical trials. However, there are limited data available showing whether the same results could be reproduced in real-world practice on an Indian population. Our objective was to determine the effectiveness and tolerability of fondaparinux in the management of symptomatic ACS in real-world clinical practice. The EMR data of hospitalized ACS patients (n = 611), from January 2015 to January 2020, representing UA or NSTEMI or STEMI and were prescribed fondaparinux (2.5 mg once daily) to manage ACS were analyzed. The effectiveness was analyzed as recurrence of ACS and tolerability as total incidence of major bleeding during hospitalization, at 30 days and 180 days. Appropriate statistical analysis was used with a statistically significance of p value < 0.05. The incidence of recurrent ACS was not seen during hospitalization and in the first 30 days, while in only 0.65% (n = 4) patients, ACS reoccurred within 180 days. In a mean duration of 172.75 ± 3.20 days, UA was reported in 0.49% (n = 3) patients, NSTEMI in 0.16% (n = 1) of patients, and STEMI was not documented. None of the major bleeding events occurred during the entire study period, whereas minor bleeding events were reported during hospitalization 0.98% (n = 6) and at 30 days 0.16% (n = 1). The bleeding events were statistically insignificant (p value > 0.05). No incidences of stent thrombosis were reported during the entire study period. In the real world, fondaparinux was found to be effective and tolerable when used to manage symptomatic ACS patients regardless of revascularization procedure with no incidence of stent thrombosis, and minimal recurrent ACS and insignificant increase in bleeding events.
Identifiants
pubmed: 35138595
doi: 10.1007/s40119-022-00253-x
pii: 10.1007/s40119-022-00253-x
pmc: PMC8933594
doi:
Types de publication
Journal Article
Langues
eng
Pagination
129-141Informations de copyright
© 2022. The Author(s).
Références
Sanchis-Gomar F. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016;4(13):256. https://doi.org/10.21037/atm.2016.06.33 .
doi: 10.21037/atm.2016.06.33
pubmed: 27500157
pmcid: 4958723
Shah S, et al. Comparative evaluation of efficacy, safety and haemostatic parameters of enoxaparin and fondaparinux in unstable coronary artery disease. J Clin Diagn Res. 2014;8(1):31–4. https://doi.org/10.7860/JCDR/2014/6359.3908 .
doi: 10.7860/JCDR/2014/6359.3908
pubmed: 24596717
pmcid: 3939573
Chaturvedi V, Karthikeyan G. Fondaparinux in acute coronary syndromes. Expert Opin Drug Metab Toxicol. 2009;5(12):1615–23. https://doi.org/10.1517/17425250903456039 .
doi: 10.1517/17425250903456039
pubmed: 19929450
Overbaugh KJ. Acute coronary syndrome. Am J Nurs. 2009;109(5):42–53. https://doi.org/10.1097/01.NAJ.0000351508.39509.e2 .
doi: 10.1097/01.NAJ.0000351508.39509.e2
pubmed: 19411905
Amsterdam EA, et al.AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology American Heart Association task force on practice guidelines. Circulation. 2014;23(25):344–426. https://doi.org/10.1161/CIR.0000000000000134 .
doi: 10.1161/CIR.0000000000000134
Bassand JP, et al. Efficacy and safety of fondaparinux in patients with acute coronary syndromes. Expert Rev Cardiovasc Ther. 2007;5(6):1013–26. https://doi.org/10.1586/14779072.5.6.1013 .
doi: 10.1586/14779072.5.6.1013
pubmed: 18035917
Grech Ever D, Ramsdale DR. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. BMJ. 2003;326:1259. https://doi.org/10.1136/bmj.326.7401.1259 .
doi: 10.1136/bmj.326.7401.1259
pubmed: 12791748
pmcid: 1126130
Grech ED, Ramsdale DR. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. BMJ. 2003;326:1259. https://doi.org/10.1136/bmj.326.7401.1259 .
doi: 10.1136/bmj.326.7401.1259
pubmed: 12791748
pmcid: 1126130
Makki N, et al. Acute coronary syndrome. J Intensive Care Med. 2015;30(4):186–200. https://doi.org/10.1177/0885066613503294 .
doi: 10.1177/0885066613503294
pubmed: 24047692
Adam AM, et al. Prognostic value of blood count parameters in patients with acute coronary syndrome. Indian Heart J. 2018;70(2):233–40. https://doi.org/10.1016/j.ihj.2017.06.017 .
doi: 10.1016/j.ihj.2017.06.017
pubmed: 29716700
Turpie AG. Fondaparinux in the management of patients with ST-elevation acute myocardial infarction. Vasc Health Risk Manag. 2006;2(4):371–8. https://doi.org/10.2147/vhrm.2006.2.4.371 .
doi: 10.2147/vhrm.2006.2.4.371
pubmed: 17323591
pmcid: 1994017
Eikelboom JW, et al. Unfractionated heparin and low-molecular-weight heparin in ACS without ST elevation: a meta-analysis [published correction appears in Lancet 2000 Aug 12;356(9229):600]. Lancet. 2000;355(9219):1936–42. https://doi.org/10.1016/S0140-6736(00)02324-2 .
doi: 10.1016/S0140-6736(00)02324-2
pubmed: 10859038
Antman EM, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354(14):1477–88. https://doi.org/10.1056/NEJMoa060898 .
doi: 10.1056/NEJMoa060898
pubmed: 16537665
Karthikeyan G, et al. Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. Expert Rev Cardiovasc Ther. 2009;7(3):241–9. https://doi.org/10.1586/14779072.7.3.241 .
doi: 10.1586/14779072.7.3.241
pubmed: 19296760
Moon JY, et al. The role of oral anticoagulant therapy in patients with acute coronary syndrome. Ther Adv Hematol. 2017;8(12):353–66. https://doi.org/10.1177/2040620717733691 .
doi: 10.1177/2040620717733691
pubmed: 29204262
pmcid: 5703114
Onwordi EN, et al. Anticoagulant therapy for acute coronary syndromes. Interv Cardiol. 2018;13(2):87–92. https://doi.org/10.15420/icr.2017:26:1 .
doi: 10.15420/icr.2017:26:1
pubmed: 29928314
pmcid: 5980649
Caterina DR, Goto S. Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges. Vascul Pharmacol. 2016;81(6):1–14. https://doi.org/10.1016/j.vph.2016.03.003 .
doi: 10.1016/j.vph.2016.03.003
pubmed: 26994821
Hamedi N, Wright P. Fondaparinux and acute coronary syndrome. Br J. 2013;7(11):15–26. https://doi.org/10.12968/bjca.2012.7.11.545 .
doi: 10.12968/bjca.2012.7.11.545
Soeiro ADM, et al. Fondaparinux versus enoxaparin—which is the best anticoagulant for acute coronary syndrome? Brazilian Registry Data. Arq Bras Cardiol. 2016;107(3):239–44. https://doi.org/10.5935/abc.20160127 .
doi: 10.5935/abc.20160127
pubmed: 27579543
pmcid: 5053192
Brito V, et al. Factor Xa inhibitors for acute coronary syndromes. Cochrane Database Syst Rev. 2011;1:7038. https://doi.org/10.1002/14651858.CD007038.pub2 .
doi: 10.1002/14651858.CD007038.pub2
Wienbergen H, Zeymer U. Management of acute coronary syndromes with fondaparinux. Vasc Health Risk Manag. 2007;3(3):321–9.
pubmed: 17703640
pmcid: 2293968
Trailokya A, et al. Fondaparinux in acute coronary syndromes. J Assoc Physicians India. 2015;63(7):83–7.
pubmed: 26731838
Larmore C, et al. Real-world comparison of prasugrel with ticagrelor in patients with ACS treated with percutaneous coronary intervention in the United States. Catheter Cardiovasc Interv. 2016;88(4):535–44. https://doi.org/10.1002/ccd.26279 .
doi: 10.1002/ccd.26279
pubmed: 26577386